These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14552912)

  • 1. Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease.
    Ryu JK; Kim SU; McLarnon JG
    Exp Neurol; 2003 Oct; 183(2):700-4. PubMed ID: 14552912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
    Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
    Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
    Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
    Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
    Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
    Ryu JK; Kim SU; McLarnon JG
    Exp Neurol; 2004 May; 187(1):150-9. PubMed ID: 15081596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G; Chen Q; Reiner A
    Exp Neurol; 1997 Aug; 146(2):444-57. PubMed ID: 9270055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
    Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
    Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
    Ryu JK; Choi HB; McLarnon JG
    Neuroscience; 2006 Sep; 141(4):1835-48. PubMed ID: 16809003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.
    Pérez-Navarro E; Akerud P; Marco S; Canals JM; Tolosa E; Arenas E; Alberch J
    Neuroscience; 2000; 98(1):89-96. PubMed ID: 10858615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
    Shear DA; Dong J; Gundy CD; Haik-Creguer KL; Dunbar GL
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
    Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types.
    Figueredo-Cardenas G; Harris CL; Anderson KD; Reiner A
    Exp Neurol; 1998 Feb; 149(2):356-72. PubMed ID: 9500958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.
    Popoli P; Pintor A; Domenici MR; Frank C; Tebano MT; Pèzzola A; Scarchilli L; Quarta D; Reggio R; Malchiodi-Albedi F; Falchi M; Massotti M
    J Neurosci; 2002 Mar; 22(5):1967-75. PubMed ID: 11880527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease.
    Emerich DF; Mooney DJ; Storrie H; Babu RS; Kordower JH
    Neurotox Res; 2010 Jan; 17(1):66-74. PubMed ID: 19588214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism.
    Jamwal S; Singh S; Kaur N; Kumar P
    Neurotox Res; 2015 Aug; 28(2):171-84. PubMed ID: 26078029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific reactions of different striatal neuron types in morphology induced by quinolinic acid in rats.
    Feng Q; Ma Y; Mu S; Wu J; Chen S; Ouyang L; Lei W
    PLoS One; 2014; 9(3):e91512. PubMed ID: 24632560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.
    Beal MF; Ferrante RJ; Swartz KJ; Kowall NW
    J Neurosci; 1991 Jun; 11(6):1649-59. PubMed ID: 1710657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington's disease.
    Meade CA; Figueredo-Cardenas G; Fusco F; Nowak TS; Pulsinelli WA; Reiner A
    Exp Neurol; 2000 Dec; 166(2):307-23. PubMed ID: 11085896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.
    Giampà C; Patassini S; Borreca A; Laurenti D; Marullo F; Bernardi G; Menniti FS; Fusco FR
    Neurobiol Dis; 2009 Jun; 34(3):450-6. PubMed ID: 19281846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of mitochondrial function by paliperidone attenuates quinolinic acid-induced behavioural and neurochemical alterations in rats: implications in Huntington's disease.
    Mishra J; Kumar A
    Neurotox Res; 2014 Nov; 26(4):363-81. PubMed ID: 24752928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.